News & updates.
Product launches, regulatory milestones, partnerships, and research from HeartSciences.
Fortitude Invests $1.0 Million in HeartSciences at a 22% Premium with No Adjustment to the Merger Consideration
Fortitude Mining Holdings purchased 411,522 shares of HeartSciences common stock for approximately $1.0 million in a private placement at a 22% premium to market, with no change to the merger exchange ratio.
Read storyHeartSciences Files Preliminary Proxy Statement for Business Combination with Fortitude Mining Holdings; Provides Business Update and Reports Fiscal 2026 Financial Results
HeartSciences filed its preliminary proxy statement for the proposed business combination with Fortitude Mining Holdings and reported no meaningful revenue and $1.7 million in cash for the fiscal year ended April 30, 2026.
Read storyEuropean Patent Granted for ECG-Based Assessment of Diastolic Function, Expands HeartSciences' Patent Portfolio to More Than 45 Granted Patents
The European Patent Office has granted European Patent No. EP4252651 covering ECG-based assessment of diastolic function, taking effect as a Unitary Patent across 19 European countries and expanding HeartSciences' portfolio to more than 45 granted patents.
Read storyHeartSciences Launches MyoVista Insights™ Version 1.3 with AI-ECG Algorithm Marketplace and First FDA-Cleared Algorithm
Version 1.3 introduces the MyoVista Insights AI-ECG Algorithm Marketplace, launching with an FDA-cleared ECG-EF model from Bunkerhill Health that detects reduced left ventricular ejection fraction from a routine ECG.
Read storyHeartSciences Signs Commercial Agreement with North Shore Health, the First Hospital Deployment from the Cibolo Health Network
North Shore Health, part of the Cibolo Rural Health Networks, has signed a commercial agreement to deploy MyoVista Insights — the first hospital deployment within the Cibolo Health network following its endorsement of the platform.
Read storyUniversity of West England Adopts HeartSciences' MyoVista Insights Platform and MyoVista wavECG™ Device to Establish ECG Education and Technology Reference Center
The University of the West of England has adopted MyoVista Insights and the MyoVista wavECG device as its exclusive ECG technologies, establishing a Reference Center for ECG Education and Technology that trains the next generation of NHS cardiac scientists.
Read storyCibolo Health Designates MyoVista Insights as Endorsed ECG Management Platform for 123 Hospitals
Cibolo Rural Health Networks has selected MyoVista Insights as its endorsed ECG management platform for the 123 independent hospitals across six states inside its high-value networks.
Read storyHeartSciences Announces FDA 510(k) Submission for MyoVista wavECG Device
The MyoVista wavECG device — a 12-lead ECG platform designed to host AI-ECG algorithms — has been submitted to the FDA for 510(k) premarket clearance.
Read storyMajor Upgrade to MyoVista Insights Platform — Commercial Launch Version 1.1
Version 1.1 ships a redesigned worklist, longitudinal ECG comparison overlays, and a faster waveform caliper — built around feedback from early-adopter clinicians.
Read storyMyoVista Insights AI-ECG Algorithm for Aortic Stenosis Receives FDA Breakthrough Device Designation
The FDA granted Breakthrough Device Designation to a MyoVista Insights algorithm targeting earlier detection of aortic stenosis.
Read storyAI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement
Centers for Medicare & Medicaid Services have published reimbursement assignment for AI-ECG analysis services using MyoVista technology.
Read storyHeartSciences and Rutgers University Announce Multi-Year AI-ECG Collaboration
A multi-year collaboration with Rutgers Robert Wood Johnson Medical School expands the AI-ECG algorithm pipeline and clinical validation footprint.
Read storyHeartSciences Signs First SaaS Revenues Agreement Following Full Launch of MyoVista Insights
St. Vincent Health has signed a commercial SaaS agreement for MyoVista Insights, HeartSciences' first mainstream revenue-generating deployment following the platform's full launch at ACC.
Read storyHeartSciences' MyoVista Insights Receives Epic Toolbox Designation for ECG Management System Category
MyoVista Insights has been added to Epic Toolbox, meeting Epic's recommended practices for ECG management system integrations via HL7v2, SSO, and SMART on FHIR.
Read storyFoundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences' Patent Portfolio
The USPTO has granted a foundational patent covering estimation of echocardiography parameters of heart function from an ECG, bringing HeartSciences' total to 44 granted patents.
Read storyHeartSciences Signs First MyoVista Insights Platform Customer, Marking Major Commercial Milestone
Westcliffe Health Innovations, a UK NHS cardiology provider, becomes the first commercial customer for the MyoVista Insights platform.
Read storyHeartSciences Closes Non-Dilutive Financing to Increase its Cash Runway Ahead of Upcoming FDA Submission
A $1.9 million non-dilutive loan note extends the Company's capital runway ahead of its planned FDA submissions.
Read storyHeartSciences Announces Allowance of U.S. Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction
The USPTO has allowed a patent covering deep-learning detection of left and/or right ventricular dysfunction from the ECG.
Read storyHeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio: Granted Indian Patent for its MyoVista Wavelet Technology
The Indian Patent Office has granted HeartSciences a patent covering its MyoVista wavelet technology, bringing the Company's total to 44 granted patents.
Read storyHeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG
The European Patent Office has granted a patent covering the use of AI-ECG for any echo measure of diastolic function of the heart.
Read storyHeartSciences Announces Peer-Reviewed Publication Evaluating Use of MyoVista Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes
A study published in Cardiovascular Diabetology found the MyoVista AI-ECG model outperformed NT-proBNP and the ARIC HF score for Stage B heart failure screening in type 2 diabetes patients.
Read storyHeartSciences Announces Canada Patent Grant Covering MyoVista Wavelet Technology
The Canadian Intellectual Property Office has granted HeartSciences a patent covering its MyoVista wavelet technology.
Read storyHeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway
The FDA confirmed a switch from the De Novo process to a standard 510(k) submission for the MyoVista wavECG device and its AI-ECG algorithm.
Read storyHeartSciences Receives Two New Patent Allowances, Expanding its International Patent Portfolio
New patent allowances from Brazil and the UAE bring HeartSciences' portfolio to 33 international and 9 US granted or allowed patents.
Read storyHeartSciences Signs Definitive Agreements with the Icahn School of Medicine at Mount Sinai to Commercialize Artificial Intelligence Cardiovascular Algorithms
HeartSciences has executed definitive license agreements and a memorandum of understanding with Icahn Mount Sinai to commercialize AI cardiovascular algorithms.
Read storyHeartSciences Signs Distribution Agreement with MedPhy Technologies, Mumbai, India
MedPhy Technologies will import and distribute the MyoVista wavECG in India once full product rollout begins.
Read storyHeartSciences Signs Distribution Agreement with FJ Medical, Denmark
FJ Medical will distribute the MyoVista wavECG across the Nordic countries of Denmark, Sweden, Norway and Finland.
Read storyHeartSciences Announces Further Expansion of Artificial Intelligence Patent Portfolio: European Patent Allowed for Quantification by an ECG of Key Heart Measures Using AI
The European Patent Office has allowed a patent covering AI-based quantification of echocardiographic heart-function measures from an ECG.
Read storyHeartSciences Announces Completion of Patient Enrollment for FDA Pivotal Study of MyoVista wavECG
HeartSciences has completed patient enrollment in its 600-plus-patient, five-center pivotal study validating the MyoVista wavECG AI algorithm for FDA submission.
Read storyHeartSciences Granted Key Israeli International Patent for its MyoVista Wavelet Technology Utilizing Artificial Intelligence for Early Detection of Heart Disease
The Israel Patent Office has granted HeartSciences a patent covering its MyoVista wavelet technology, bringing its total to 40 granted patents.
Read storyHeartSciences Announces Further Internationalization of its Patent Portfolio: Granted Korean Patent for its MyoVista Wavelet Technology
The Korean Intellectual Property Office has granted HeartSciences a patent covering its MyoVista wavelet technology.
Read storyHeartSciences Granted European Patent for Proprietary Electrode and Cable Connections for Use with its AI-Based MyoVista ECG
The European Patent Office has granted a patent covering HeartSciences' proprietary electrode and cable-connector design for the MyoVista device.
Read storyHeartSciences Announces Major Milestone with the Issuance of CPT Codes by the American Medical Association for ECG AI Analysis of Cardiac Dysfunction
The AMA has issued new Category III CPT codes for AI-assistive ECG cardiac dysfunction risk assessment, expected to cover HeartSciences' MyoVista algorithm.
Read storyHeartSciences Granted U.S. Patent for ECG Assessment of Heart Diastolic Function Using Artificial Intelligence
The USPTO has granted a patent for ECG quantification of diastolic-function measures using AI, bringing HeartSciences' total to 18 granted patents.
Read storyHeart Test Laboratories, Inc. Announces Pricing of $6.375 Million Initial Public Offering and Nasdaq Listing
HeartSciences priced its IPO at $4.25 per unit for approximately $6.375 million in gross proceeds and began trading on Nasdaq under HSCS / HSCSW.
Read storyHeartSciences Announces Baker Institute ECG LV Dysfunction Study Results Published in JACC — Cardiovascular Imaging
A study by Australia's Baker Heart and Diabetes Institute found MyoVista wavECG-based machine learning could reduce unnecessary echocardiography referrals by 45% while missing only 12% of LV dysfunction cases.
Read storyHeartSciences Announces Pilot Study Results Published in Launch Edition of European Heart Journal — Digital Health
A pilot study found MyoVista technology could help predict abnormal coronary artery calcium scores from a surface ECG.
Read storyHeartSciences Announces Clinical Study Results in the Journal of the American College of Cardiology (JACC)
A 1,202-subject, four-center study found MyoVista wavECG-based machine learning could cost-effectively identify left ventricular dysfunction, with an AUC of 0.94 for age- and sex-adjusted LVDD prediction.
Read storyHeartSciences Announces De Novo Submission to FDA for Innovative MyoVista wavECG Device
HeartSciences submitted the MyoVista wavECG device to the FDA via the De Novo premarket review pathway, supported by clinical data from three institutions.
Read story